# Skyrizi

NDC: 0074-5015
Generic name: risankizumab-rzaa
Labeler / Manufacturer: AbbVie Inc.
Product type: HUMAN PRESCRIPTION DRUG
Marketing category: Biologic License Application
Dosage form: INJECTION
Routes: INTRAVENOUS
Marketing started: 20220616

FDA application: BLA761262

## Active ingredients

- RISANKIZUMAB: 600 mg/10mL

## Pharmacological class

—

## External sources

- openFDA: https://api.fda.gov/drug/ndc.json?search=product_ndc:"0074-5015"
- FDA NDC Directory: https://www.accessdata.fda.gov/scripts/cder/ndc/dsp_searchresult.cfm?p_ndc=0074-5015
- DailyMed: https://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=7148c8eb-b39e-e20a-6494-a6df82392858